Ina Wellmann

Mrs. Ina Wellmann


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
LKLaura Khil
Laura Khil
JHJan Heidrich
Jan Heidrich
IWIna Wellmann
Ina Wellmann
VKVanessa Kääb-Sanyal
Vanessa Kääb-Sanyal
SWStefanie Weigel
Stefanie Weigel
OHOliver Heidinger
Oliver Heidinger
Background: The European Guidelines for breast cancer screening suggest that the impact of population-based mammography screening programmes (MSP) may be assessed using the relative reduction in the incidence of advanced breast cancer (ABC, that is, stage UICC II and higher) as a surrogate indicator of screening effectiveness. Methods: This prospective, population register-based study contained individual data of 1,200,246 women (aged 50–69 years) who attended the initial prevalence screening between 2005 and 2009. Of them, 498,029 women returned for the regular (i.e., within 24 months) first subsequent, and 208,561 for the regular second subsequent incidence screenings. The incidence rate of ABC was calculated for the 24-months period following, but not including, the initial screening by incorporating all interval ABCs and all ABCs detected at the regular first incidence screening; the ABC rate for the second 24-months period was determined in the same way, including ABCs detected in the interval after the first and, respectively, at the second incidence screening. The relative reduction in the ABC incidence was derived by comparing the age-standardized rates in these two periods with an age-standardized reference incidence rate, observed in the target population before the MSP implementation. The strengths and weaknesses of this particular study design were contrasted with a recently published checklist of main methodological problems affecting studies of the effect of MSP on ABC incidence. Results: The age-standardized ABC incidence rate was 291.6 per 100,000 women for the 24-months period subsequent to the initial screening, and 275.0/100,000 for the 24-months period following the first subsequent screening. Compared to the 2-year incidence of 349.4/100,000 before the start of the MSP, this amounted to a relative reduction of 16.5 and 21.3%, respectively, in the incidence of ABC among regular MSP participants. Conclusions: The design employed in this study avoids some of the substantial methodological limitations that compromised previous observational studies. Nevertheless, specific limitations prevail that demand a cautious interpretation of the results. Therefore, the study findings, indicating a reduction in ABC for regular MSP participants, need to be followed with respect to potential impacts on breast cancer mortality rates.

6 September 2024 in Cancer Epidemiology
Verified
Journal Article
Open access
ASAndreas Stang
Andreas Stang
IWIna Wellmann
Ina Wellmann
BHBernd Holleczek
Bernd Holleczek
SKSoo-Zin Kim-Wanner
Soo-Zin Kim-Wanner
JMJacqueline Müller-Nordhorn
Jacqueline Müller-Nordhorn
HKHiltraud Kajüter
Hiltraud Kajüter
Due to the rarity of pancreatic neuroendocrine neoplasms, only few population-representative studies on incidence and survival have been conducted. The aim was to provide up-to-date nationwide incidence and relative survival estimates of neuroendocrine (NE) neoplasms overall, NE tumors (NETs), NE carcinomas (NECs), and mixed NE neoplasms (MiNEN). We distinguished between pancreatic NETs (functioning versus non-functioning), NECs and mixed NE neoplasms and analyzed data from 2009 through 2021 from all German cancer registries covering a population of more than 80 million. We calculated crude and age-standardized incidence rates and 5-year relative survival estimates (RS). Overall 6474, 4217, and 243 patients with pancreatic NETs, NECs, and mixed NE neoplasms, respectively were registered. While the age-standardized incidence of NETs has increased (+16.4 % per year, 95 %CI 12.2;20.7), the incidence of NEC has fallen (about -6.4 % per year, 95 %CI -8.0; -4.8). The crude RS was 77.7 % (standard error [SE] 0.9) for non-functioning NETs, 90.3 % for functioning NETs (SE 3.9), and 18.5 % (SE 3.9) for MiNEN. Large and small cell NECs had a low RS (9.1 % and 6.9 %, respectively). RS for G1 NETs was 88.2 %, while it was only 36.6 % for G3 NETs. Localized NETs had a RS of 92.8 %, while distant metastatic NETs had a RS of 45.0 %. The incidence of pancreatic NETs has increased markedly in Germany in the period 2009-2021. Subgroups of NETs (G1 grading or localized stage) have an excellent prognosis. RS of MiNEN is more similar to NECs than NETs.

20 February 2025 in International Journal of Cancer
Verified
Journal Article
Open access
LMLennart Möller
Lennart Möller
ASAndras Szentkirályi
Andras Szentkirályi
CEChristine Eisfeld
Christine Eisfeld
IWIna Wellmann
Ina Wellmann
FRFranziska Rees
Franziska Rees
ASAndreas Stang
Andreas Stang
Neuroendocrine neoplasms (NENs) of the colon and rectum are a heterogeneous group of epithelial neoplasms with neuroendocrine differentiation. They include well‐differentiated neuroendocrine tumors (NETs), poorly differentiated neuroendocrine carcinomas (NECs) and mixed neuroendocrine‐non‐neuroendocrine neoplasms (MiNENs). Our aim was to calculate incidence, incidence trends and relative survival for colonic and rectal NETs, NECs, and MiNENs. We analyzed data covering the entire German population recorded between 2009 and 2021, calculating age‐standardized incidence rates, annual percent changes, and the relative 5‐year survival probability for the calendar period 2017–2021. Our comprehensive analyses included 12,602 NEN cases, with 59% located in the rectum. NECs, MiNENs and tumors with colonic location showed higher stages. We observed an increase in the incidence of NETs, particularly in patients aged <55 years, and in the incidence of MiNENs, and a constant incidence of NECs. The relative five‐year survival was high for rectal NETs (95.9%, 95%‐CI 94.6; 97.1) and colonic NETs (81.4%, 95%‐CI 78.3; 84.5) and low for colonic NECs (20.5%, 95%‐CI 17.6; 23.4) and rectal NECs (19.2%, 95%‐CI 15.7; 22.6). The increase in the incidence of NETs might be partly due to colorectal cancer screening, improved diagnostics, and changes in classification of NETs. We attribute the increase in incidence of MiNENs to the recent introduction of this morphological category. Higher stages at diagnosis, a higher proportion of NECs and higher median age at diagnosis may contribute to the less favorable survival probabilities associated with colonic as opposed to rectal location.

30 January 2024 in BMC Medicine
Verified
Journal Article
Open access
PDF file
LBLaura Buschmann
Laura Buschmann
IWIna Wellmann
Ina Wellmann
NBNadine Bonberg
Nadine Bonberg
JWJürgen Wellmann
Jürgen Wellmann
HHHans-Werner Hense
Hans-Werner Hense
HMHeike Minnerup
Heike Minnerup
Background: Mammography screening programmes (MSP) aim to reduce breast cancer mortality by shifting diagnoses to earlier stages. However, it is difficult to evaluate the effectiveness of current MSP because analyses can only rely on observational data, comparing women who participate in screening with women who do not. These comparisons are subject to several biases: one of the most important is self-selection into the MSP, which introduces confounding and is difficult to control for. Here, we propose an approach to quantify confounding based on breast cancer survival analyses using readily available routine data sources. Methods: Using data from the Cancer Registry of North Rhine-Westphalia, Germany, we estimate the relative contribution of confounding to the observed survival benefit of participants of the German MSP. This is accomplished by comparing non-participants, participants with screen-detected and participants with interval breast cancers for the endpoints “death from breast cancer” and “death from all causes other than breast cancer” — the latter being assumed to be unrelated to any MSP effect. By using different contrasts, we eliminate the effects of stage shift, lead and length time bias. The association of breast cancer detection mode with survival is analysed using Cox models in 68,230 women, aged 50–69 years, with breast cancer diagnosed in 2006–2014 and followed up until 2018. Results: The hazard of dying from breast cancer was lower in participants with screen-detected cancer than in non-participants (HR = 0.21, 95% CI: 0.20–0.22), but biased by lead and length time bias, and confounding. When comparing participants with interval cancers and non-participants, the survival advantage was considerably smaller (HR = 0.62, 95% CI: 0.58–0.66), due to the elimination of stage shift and lead time bias. Finally, considering only mortality from causes other than breast cancer in the latter comparison, length time bias was minimised, but a survival advantage was still present (HR = 0.63, 95% CI: 0.56–0.70), which we attribute to confounding. Conclusions: This study shows that, in addition to stage shift, lead and length time bias, confounding is an essential component when comparing the survival of MSP participants and non-participants. We further show that the confounding effect can be quantified without explicit knowledge of potential confounders by using a negative control outcome.

6 June 2024 in Cancers
Verified
Journal Article
Open access
PDF file
ASAndreas Stang
Andreas Stang
LMLennart Möller
Lennart Möller
IWIna Wellmann
Ina Wellmann
KCKevin Claassen
Kevin Claassen
HKHiltraud Kajüter
Hiltraud Kajüter
Jürgen C. BeckerJürgen C. Becker
Jürgen C. Becker
Background: To date, only a few population-representative studies have been carried out on the rare Merkel cell carcinoma (MCC). We provide incidence and survival estimates of MCC, including the conditional relative survival. Methods: We analyzed data from the cancer registry of North Rhine-Westphalia, Germany, 2008–2021, covering a population of 18 million. We included all newly diagnosed MCCs and calculated age-standardized (old European Standard population) incidence rates and unconditional and conditional relative survival. Results: Our analysis included 2164 MCC patients. The age-standardized incidence of MCC was 5.2 (men) and 3.8 (women) per million person-years. The 5-year relative survival was 58.8% (men) and 70.7% (women). Survival was lower among men than women in all age–sex groups and was highest for MCC of the upper extremity in both men (68.2%) and women (79.3%). The sex difference in survival is particularly due to the better survival of women with MCC of the head and neck. In terms of survival, the first two years are particularly critical. Conclusions: Our data validate the worse survival among men and highlights a more favorable prognosis for MCCs located on the limbs. The first two years after diagnosis of MCC are the years with the highest excess mortality.

12 December 2025 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Open access
KNKhodr Cheikh El Najjarine
Khodr Cheikh El Najjarine
HKHiltraud Kajüter
Hiltraud Kajüter
IWIna Wellmann
Ina Wellmann
ASAndreas Stang
Andreas Stang
Chalid AssafChalid Assaf
Chalid Assaf
Summary: Background: Primary cutaneous lymphomas (PCL) are primarily composed of cutaneous T‐cell lymphomas (CTCL), followed by cutaneous B‐cell lymphomas (CBCL). This study aimed to assess the incidence and survival rates of PCL in Germany. Methods: We analyzed data from the North Rhine‐Westphalia Cancer Registry (2008–2021), which covers a population of 18 million. Age‐standardized incidence rates and relative survival were calculated. Results: The analysis included 3,853 patients with newly diagnosed PCL. Of these, 69.5% were CTCL, and 24.9% were CBCL. The age‐standardized incidence of PCL was 10.8 per million person‐years. The incidence of both CTCL and CBCL increased over time. PCL cases were also identified in children. The overall five‐year relative survival for PCL was 89% (95% CI: 87–92%), with CTCL patients having a survival rate of 91% (95% CI: 88–94%) and CBCL patients of 86% (95% CI: 81–91%). Among patients with Sézary syndrome, the five‐year relative survival was 53% (95%: CI:29–77%). Conclusions: This study represents the largest population‐based analysis of PCL in Germany, including both adults and children. The incidence of PCL was higher than previously reported. Additionally, we present the first survival data for PCL in Germany, revealing a notably higher survival probability for patients with Sézary syndrome.